217 related articles for article (PubMed ID: 21455866)
1. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
Walenga JM; Jackson CM; Kessler CM
Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
[TBL] [Abstract][Full Text] [Related]
2. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
3. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
4. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
5. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
6. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
8. Development of generic low molecular weight heparins: a perspective.
Fareed J; Leong W; Hoppensteadt DA; Jeske WP; Walenga J; Bick RL
Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
[TBL] [Abstract][Full Text] [Related]
9. The United States Food and Drugs Administration approves a generic enoxaparin.
Ofosu FA
Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
[TBL] [Abstract][Full Text] [Related]
10. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
[TBL] [Abstract][Full Text] [Related]
12. New and generic anticoagulants and biosimilars: safety considerations.
Kalodiki E; Fareed J
Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
[TBL] [Abstract][Full Text] [Related]
13. Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology .
Harenberg J; Kalodiki E; Walenga JM;
Int Angiol; 2012 Apr; 31(2):101-4. PubMed ID: 22466973
[No Abstract] [Full Text] [Related]
14. Low molecular weight heparins in the outpatient management of venous thromboembolism.
Bick RL
Semin Thromb Hemost; 1999; 25 Suppl 3():97-9. PubMed ID: 10549723
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic equivalence of complex drugs.
Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparins copies: are they considered to be generics or biosimilars?
Minghetti P; Cilurzo F; Franzé S; Musazzi UM; Itri M
Drug Discov Today; 2013 Mar; 18(5-6):305-11. PubMed ID: 23153556
[TBL] [Abstract][Full Text] [Related]
17. Generic forms of low-molecular-weight heparins: some practical considerations.
Leong W; Hoppensteadt DA
Clin Appl Thromb Hemost; 2003 Oct; 9(4):293-7. PubMed ID: 14653438
[TBL] [Abstract][Full Text] [Related]
18. Generic and commercial low molecular weight heparins.
Messmore HL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):253. PubMed ID: 16959678
[No Abstract] [Full Text] [Related]
19. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
Nicolau JC; Cohen M; Montalescot G
J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
[TBL] [Abstract][Full Text] [Related]
20. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
Simoens S; Huys I
Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]